CDDF
Cancer Drug Development Forum

CDDF WORKSHOP

NEW FRONTIERS IN THE USE AND DEVELOPMENT OF COMPANION DIAGNOSTICS

BRUSSELS, BELGIUM 11-12 DECEMBER 2014

PROGRAMME



DETAILED PROGRAMME

DAY 1 THURSDAY 11 DECEMBER 2014

ROOM : IMBUIA

13:00 WELCOME AND INTRODUCTION

SESSION 1 : TOWARDS PRECISION MEDICINE

Session Chairs
Silvia Marsoni *(Cancer Institute of Candiolo - FPO-IRCCS, Italy)*
Joachim Reischl *(Bayer, Germany)*

13:15 Impact of tumour integrity and genomic instability in cancer treatment
Marco Gerlinger (Institute of Cancer Research, UK)

13:35 Pros & cons of using liquid biopsies
Federica Dinicolantonio (University of Torino, Italy)

13:55 Proteomics based CDx for immunotherapies, the diagnostic cortex and surrogate endpoints
Heinrich Roder (Biodesix, USA)

14:15 EORTC SPECTA initiative , a multitumour programme for precision medicine in Europe
Denis Lacombe (EORTC, Belgium)

15:00 FUNNEL: infrastructuring for precision medicine trials in colorectal cancer
Silvia Marsoni (Cancer Institute of Candiolo - FPO-IRCCS, Italy)

15:20 BREAK

15:50 Nanoparticles as a tool for the localisation of cancer cells and stem cells
Alexander Seifalian (University College London,UK)

16:10 Role of microRNA in companion diagnsotics of cancer
Barbara Selinger (Martin-Luther-University, Germany)

16:30 Regulatory approaches to embrace new technology trends for patient stratification
Elizabeth Mansfield (FDA, USA)

16:50 Biomarkers in solid tumors: the pathologist perspective
Paul van Diest (University Medical Center Utrecht, The Netherlands)

17:10 Discussion

18:00 END OF THE WORKSHOP

19:00 DINNER at Brasserie 135

DAY 2 FRIDAY 12 DECEMBER 2014

ROOM : IMBUIA

SESSION 2 : HIC SUNT LEONES: BIOMARKERS IN IMMUNOTHERAPY

Session Chairs
Leif Hakansson *(University Hospital of Linkoping,Sweden)*

08:30	Introduction - Which are the hurdles *Leif Håkansson (University Hospital of Linkoping ,Sweden)*
08:40	Impact of tumour infiltrating lymphocytes for immunotherapeutic efficacy *Federica Marchesi (Humanitas Clinical and Research Center-University of Milan, Italy)*
09:00	Predictive value of regulatory T-cells and MDSC for response to immunotherapy *Marcella Tazzari (Istituto Nazionale dei Tumori, Italy)*
09:20	Biomarkers for monitoring cancer vaccines *To be announced*
09:40	PD1 as biomarker *To be announced*
10:00	PDL1 *To be announced*
10:20	BREAK
10:45	3D cell culture as a tool for biomarker development *Arno Amann (Medizinische Universität Innsbruck, Austria)*
11:05	Discussion

SESSION 3 / LOGISTIC STRATEGIES FOR COMPANION DIAGNOSTICS

Session Chairs
Christina Bender *(Novartis, Switzerland)*
Lothar Bergmann *(Medizinische Klinik - J.W. Goethe Universität,Germany)*

11:30	Regulatory challenges of CDx development *Harald Enzmann (Bfarm, Germany)*
11:50	Serum banking *Angus Dalgleish (St Georges University, UK)*
12:10	Centralization of diagnostic testing in France *Jean-Christophe Sabourin (CHU Rouen, France)*
12:30	Provision of biomarker panels - who pays *Yves Cariou (Boston Healthcare Consulting, Belgium)*
12:50	Discussion
13:15	**Wrap up and next steps**
13:30	END OF THE WORKSHOP LUNCH at ECoffee

Workshop Objectives

The goal of the workshop is to discuss new frontiers of biomarkers and companion diagnostics together with experts from academia, regulatory authorities, pharmaceutical industry and payers.

Conference Committee

- Silvia Marsoni (Italy) - *Conference Chair*
- Christina Bender (Switzerland)
- Leif Hakansson (Sweden)
- Joachim Reischl (Germany)

Workshop venue

Hotel Dolce La Hulpe - Brussels
135, Chaussée de Bruxelles
1310 La Hulpe / Belgium
www.dolcelahulpe.com

Conference secretariat

CDDF office – Marjorie Recorbet
c/o ECCO – the European Cancer Organisation
Avenue E. Mounier 83
1200 Brussels
Phone: +32.2.775.02.15
marjorie.recorbet@ecco-org.eu

The Cancer Drug Development Forum (CDDF)

The Cancer Drug Development Forum (CDDF), previously known as the Biotherapy Development Association (BDA), is a not-for-profit association whose mission is to provide a unique platform to facilitate interactions between all stakeholders (academia, regulatory authorities, policymakers, the pharmaceutical industry and patient advocates) to improve the efficiency of cancer drug development.

For the past 14 years, CDDF has strived to leverage the discussion on the most promising advances in oncology drug development, uniting experts from academia, the pharmaceutical industry and regulatory authorities in the quest of overcoming the main challenges in cancer treatment.

For more information please visit:

www.cddf.org